Copyright © 2019. Inderes Oy. All rights reserved.

CellaVision

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Tiedotteet
4.2.
2021

Ahead of the Annual General Meeting (AGM) 2021 the Nomination Committee of CellaVision AB proposes that the Board shall be composed of seven directors elected at the AGM, with no alternates, for the period until the next AGM.

Tiedotteet
4.2.
2021

CellaVisions Year-end Bulletin for 2020

1 October-31 December 2020
Net sales decreased by 13% to SEK 131.0 million (149.8).
Sales decreased organically by 6% (+7).
EBITDA amounted to SEK 40.8 million (41.5).
EBITDA margin amounted to 31% (28).
Profit before tax amounted to SEK 36.4 million (35.0).
Earnings per share before and after dilution were SEK 1.20 (1.02).
Cash flow from operating activities amounted to SEK 25.6 million (24.0).

Tiedotteet
29.1.
2021

Updated phone numbers for the conference

CellaVision AB (publ) will publish the Year-end bulletin for 2020, on February 4, 2021 at 8:20 CET. The report will be available at www.cellavision.com

Tiedotteet
27.1.
2021

CellaVision AB (publ) will publish the Year-end bulletin for 2020, on February 4, 2021 at 8:20 CET. The report will be available at www.cellavision.com

In connection with the release of the Year-end bulletin for 2020, analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CET where Magnus Blixt, acting President & CEO, will present and comment the report.

Tiedotteet
1.12.
2020

The Board of Directors at CellaVision has appointed Simon Østergaard Chief Executive Officer and President. Simon Østergaard takes on his new role in March 2021, succeeding Zlatko Rihter, who left the company on November 28. Until the date of entry, Magnus Blixt continues in his role as acting CEO and then returns to his regular role as CFO.

Tiedotteet
23.10.
2020

Missing pages in the Interim Report, English version only.

1 April -30 September 2020

CellaVision

CellaVision

CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China and Japan. The company derives the majority of its revenue from the sale of analyzers.